The COX-2 rs20417 polymorphism and risk of coronary artery disease: Evidence from 17,621 subjects

Heart Lung and Circulation

Volumn 23, Issue 6, 2014, Pages 572-577

  Wang, Heng ^a   Fu, Yu ^a   Liu, Dong ^a   Zhang, Miao ^a   Zhang, Guoheng ^a   Wu, Wenbin ^a   Yang, Shijiang ^a   Li, Cunjiang ^a   Zhang, Hui ^a  

^a XUZHOU CENTRAL HOSPITAL   (China)

Author keywords

Coronary artery disease; Cox 2; Meta analysis; Polymorphism; Risk

Indexed keywords

CYCLOOXYGENASE 2; PTGS2 PROTEIN, HUMAN;

ARTICLE; ASIAN; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CAUCASIAN; CORONARY ARTERY DISEASE; ETHNICITY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTEMATIC REVIEW; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MODEL; FEMALE; GENETICS; MALE; MEDLINE; META ANALYSIS; RISK FACTOR;

ASIAN CONTINENTAL ANCESTRY GROUP; CORONARY ARTERY DISEASE; CYCLOOXYGENASE 2; FEMALE; HUMANS; MALE; MODELS, GENETIC; POLYMORPHISM, GENETIC; PUBMED; RISK FACTORS;

EID: 84904554824     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2014.01.002     Document Type: Article

References (26)

1. Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, Mayer B, et al. Genomewide association analysis of coronary artery disease. N Engl J Med 2007;357:443-53.
2. Belton OA, Duffy A, Toomey S, Fitzgerald DJ. Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis. Circulation 2003;108:3017-23.
3. Zhang X, Miao X, Tan W, Ning B, Liu Z, Hong Y, et al. Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology 2005;129:565-76.
4. Colaizzo D, Fofi L, Tiscia G, Guglielmi R, Cocomazzi N, Prencipe M, et al. The COX-2 G/C -765 polymorphism may modulate the occurrence of cerebrovascular ischemia. Blood Coagul Fibrinolysis 2006;17:93-6.
5. Li W, Xu J, Wang X, Chen J, Zhang C, Sun K, et al. Cyclooxygenase-2 (COX-2) G-765C is a protective factor for coronary artery disease but not for ischemic stroke: a meta-analysis. Atherosclerosis 2009;207:492-5.
6. Thakkinstian A, McKay GJ, McEvoy M, Chakravarthy U, Chakrabarti S, Silvestri G, et al. Systematic review and meta-analysis of the association between complement component 3 and age-related macular degeneration: a HuGE review and meta-analysis. Am J Epidemiol 2011;173:1365-79.
7. Yu H, Liu H, Wang LE, Wei Q. A functional NQO1 609C>T polymor-phism and risk of gastrointestinal cancers: a meta-analysis. PLoS One 2012;7:e30566.
8. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
9. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-48.
10. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-101.
11. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
12. Papafili A, Hill MR, Brull DJ, McAnulty RJ, Marshall RP, Humphries SE, et al. Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol 2002;22:1631-6.
13. Hegener HH, Diehl KA, Kurth T, Gaziano JM, Ridker PM, Zee RY. Polymorphisms of prostaglandin-endoperoxide synthase 2 gene, and prostaglandin-E receptor 2 gene, C-reactive protein concentrations and risk of atherothrombosis: a nested case-control approach. J Thromb Haemost 2006;4:1718-22.
14. Morgan TM, Krumholz HM, Lifton RP, Spertus JA. Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study. JAMA 2007;297:1551-61.
15. Huuskonen KH, Kunnas TA, Tanner MM, Mikkelsson J, Ilveskoski E, Karhunen PJ, et al. COX-2 gene promoter polymorphism and coronary artery disease in middle-aged men: the Helsinki sudden death study. Mediators Inflamm 2008;2008:289453.
16. Kohsaka S, Volcik KA, Folsom AR, Wu KK, Ballantyne CM, Willerson JT, et al. Increased risk of incident stroke associated with the cyclooxygenase 2 (COX-2) G-765C polymorphism in African-Americans: the Atherosclerosis Risk in Communities Study. Atherosclerosis 2008;196:926-30.
17. Xie X, Ma YT, Fu ZY, Yang YN, Wang YH, Chen BD, et al. [Study on the association of cyclooxygenase-2-765g>C and prostacyclin synthase C1117A polymorphisms and the risk of myocardialinfarction in Uigur population of Xinjiang, China]. Zhonghua Liu Xing Bing Xue Za Zhi 2008;29:598-603.
18. Ol KK, Agachan B, Gormus U, Toptas B, Isbir T. Cox-2 gene polymor-phism and IL-6 levels in coronary artery disease. Genet Mol Res 2011;10: 810-6.
19. Xiong T, Lin GS. Association of cyclooxygenase-2 genepolymorphism with susceptibility to coronary heart disease. J Clin Intern Med 2008;25:786-8.
20. Sun SY, Jin AM, Fan WH, Zhang JC. Association of cyclooxygenase-2 gene polymorphism with susceptibility to chronic periodontitis and coronary heart disease. Acta Academiae Medicinae Sinicae 2010;32:347-50.
21. Lee CR, North KE, Bray MS, Couper DJ, Heiss G, Zeldin DC. Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study. Clin Pharmacol Ther 2008;83:52-60.
22. Elesber AA, Best PJ, Lennon RJ, Mathew V, Rihal CS, Lerman LO, et al. Plasma 8-iso-prostaglandin F2alpha, a marker of oxidative stress, is increased in patients with acute myocardial infarction. Free Radic Res 2006;40:385-91.
23. Vassalle C, Botto N, Andreassi MG, Berti S, Biagini A. Evidence for enhanced 8-isoprostane plasma levels, as index of oxidative stress in vivo, in patients with coronary artery disease. Coron Artery Dis 2003; 14:213-8.
24. Hill MR, Papafili A, Booth H, Lawson P, Hubner M, Beynon H, et al. Functional prostaglandin-endoperoxide synthase 2 polymorphism predicts poor outcome in sarcoidosis. Am J Respir Crit Care Med 2006;174:915-22.
25. Lee YS, Kim H, Wu TX, Wang XM, Dionne RA. Genetically mediated interindividual variation in analgesic responses to cyclooxygenase inhibitory drugs. Clin Pharmacol Ther 2006;79:407-18.
26. Orbe J, Beloqui O, Rodriguez JA, Belzunce MS, Roncal C, Paramo JA. Protective effect of the G-765C COX-2 polymorphism on subclinical atherosclerosis and inflammatory markers in asymptomatic subjects with cardiovascular risk factors. Clin Chim Acta 2006;368:138-43.